A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

On 21 December of last year, the Danish pharmaceutical company experienced a 21% plunge in its share price following disappointing trial results for its new obesity drug, CagriSema. Amycretin is ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...